NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Drugs for the treatment of pulmonary arterial hypertension

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
 Manufacturers/sponsors Actelion Pharmaceuticals UK Ltd (bosentan) Encysive pharmaceuticals (sitaxsentan) GlaxoSmithKline (epoprostenol, ambrisentan) 	 General Age Concern Cymru Board of Community Health Councils in Wales British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland
 Pfizer Ltd (sildenafil citrate) Bayer Schering Pharma (iloprost) Patient/carer groups Afiya Trust 	 Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Public Health Service for Wales
 Age Concern England Black Health Agency British Ethnic Health Awareness Foundation British Lung Foundation Chinese National Healthy Living Centre 	 National Specialist Commissioning Advisory Group (NSCAG) NHS Alliance NHS Confederation NHS Purchasing and Supply Agency NHS Quality Improvement Scotland Scottish Medicines Consortium
 Confederation of Indian Organisations Counsel and Care Equalities National Council 	Comparator manufacturers No additional
 Help the Aged Muslim Council of Great Britain Muslim Health Network Pulmonary Hypertension Association UK Raynaud's and Scleroderma Association Scleroderma Society South Asian Health Foundation Specialised Healthcare Alliance 	 Relevant research groups British Society for Cardiovascular Research Central Cardiac Audit Database National Institute for Health Research Policy Research Institute on Ageing and Ethnicity Research Institute for the Care of Older People UK Clinical Research Network
<u>Professional groups</u>British Association for Nursing in Cardiac Care	 Assessment Group National Coordinating Centre for Health Technology Assessment

National Institute for Health and Clinical Excellence Consultation on the draft scope and provisional matrix for the appraisal of Drugs for the treatment of pulmonary arterial hypertension Issue date: October 2008

Consultees Commentators (no right to submit or appeal) British Association for Services to the West Midlands Health Technology **Assessment Collaboration** Elderly British Cardiovascular Society **Associated Guideline Groups** British Geriatrics Society To be confirmed British Heart Foundation British Society for Rheumatology Associated Public Health Groups British Thoracic Society Tbc (categorise Sarah Dunsdon National Consortium of Pulmonary although she doesn't appear on the **Hypertension Directors** matrix) • National Pulmonary Hypertension Service Primary Care Cardiovascular Society • Royal College of General **Practitioners** Royal College of Nursing Royal College of Pathologists (kidney, liver, cancer) Royal College of Physicians Royal College of Physicians' Cardiology Committee Royal Pharmaceutical Society Royal Society of Medicine – Intellectual Disabilities Forum United Kingdom Clinical Pharmacy Association Others · Department of Health Devon PCT London specialised commissioning Group South West Essex PCT Welsh Assembly Government West Midlands Specialised Commissioning Team

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists

Drugs for the treatment of pulmonary arterial hypertension Issue date: October 2008

contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.